Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Lupin Pharma
Lupin Pharma
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Drug Delivery
Aptar and Lupin to launch India’s first smart device for metered-dose inhalers
ADHERO is designed to help patients with chronic respiratory diseases track their MDI usage
Finance
Neopharma subsidiary buys Japanese injectables business
Indian pharma Lupin will also sell all related assets in Japan to Neo ALA
Lupin looks to compete with Sun Pharma in Japanese market
Wholly-owned Japanese subsidiary, Kyowa, intends to set up a manufacturing plant at Tottori, Japan, as part of expansion plans in the country
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory
Several large Indian pharma companies under US FDA scrutiny
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Pharmaceutical
Lupin set to launch generic version of Valeant diabetes drug Glumetza
The Indian firm has a 180-day exclusivity for the product
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Subscribe now